SUMMARY
On a global scale, there are approximately 11 million new cases of cancer
every year of which 1.8 million cases occur in the US. The high incidence of the
disease, its life-threatening nature and its difficult management has resulted
in a surge of interest from the pharmaceutical industry during the last decade.
At the current time, sales of products used to treat cancer are close to $ 17
billion. More than 400 companies are investigating new products and approaches
for the treatment of cancer and there are close to 450 products in clinical
trials of which 80 are in phase III. Just under half of the products in clinical
trials are based on biological agents such as vaccines, monoclonal antibodies,
cytokines, genes coding for cytokines and protein conjugates. Breast cancer and
non-small cell lung cancer have received the most attention, with respectively
100 and 90 products in clinical trials. There are more than 1000 products
undergoing preclinical in-vivo trials. There is a wide range of activity
surrounding the licensing of products in development with deals ranging from
several hundreds of thousands of dollars for technology transfer, up to many
hundreds of millions of dollars for product rights.
The 250 page report reviews the latest developments within the cancer market
in terms of emerging therapies, competition, new technology and approaches to
treatment, current and future sales, reported deals and looks at possible
scenarios for the treatment of different cancer indications during the next 5
years.
About the author
Dr Brian Minter has run Chembio, a consulting practice since 1991. Prior to
this he was a research scientist at Pfizer, a marketing manager at DSM Adeno and
Solvay Pharmaceuticals and was involved in drug registration at Solvay
Pharmaceuticals. He has presented a number of workshops on emerging cancer
therapies and is the author of several publications on cancer.
View Cart
